Cargando…
Comparison of Two Corticosteroid Pre-Infusion Regimens for Pegloticase in the United States: A Retrospective Analysis in Community Rheumatology Practices
BACKGROUND: Pegloticase is a recombinant porcine-like uricase enzyme that is FDA-approved for the treatment of chronic refractory gout in adults. Some patients receiving pegloticase develop anti-drug antibodies, which leads to both loss of pegloticase efficacy and an increased risk for infusion reac...
Autores principales: | Majjhoo, Amar, Kumar, Ada, Zdanis, Michael, LaMoreaux, Brian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6879681/ https://www.ncbi.nlm.nih.gov/pubmed/31673974 http://dx.doi.org/10.1007/s40801-019-00164-9 |
Ejemplares similares
-
Use of Pre-Infusion Serum Uric Acid Levels as a Biomarker for Infusion Reaction Risk in Patients on Pegloticase
por: Keenan, Robert T., et al.
Publicado: (2019) -
Increased Efficacy and Tolerability of Pegloticase in Patients With Uncontrolled Gout Co-Treated With Methotrexate: A Retrospective Study
por: Albert, John A., et al.
Publicado: (2020) -
Effect of Leflunomide on Pegloticase Response Rate in Patients with Uncontrolled Gout: A Retrospective Study
por: Masri, Karim Richard, et al.
Publicado: (2022) -
Retreatment with Pegloticase after a Gap in Therapy in Patients with Gout: A Report of Four Cases
por: Morton, Allan H., et al.
Publicado: (2018) -
Community Practice Experiences with a Variety of Immunomodulatory Agents Co-Administered with Pegloticase for the Treatment of Uncontrolled Gout
por: Broadwell, Aaron, et al.
Publicado: (2022)